Gilead's second-quarter results: Revenue fell 10 percent from a year earlier, with a net loss of $3.3 billion.

Guide: On July 30, local time, Gilead announced its financial results for the second quarter (Q2) and first half of 2020.
, while Gilead's reputation in 2020 was boosted by Redseweandy's reputation and launched the product in the U.S., Japan and European markets in May-June, its sales revenue in the most recent quarter was hit by a double-digit decline.
July 30 local time, Gilead announced its financial results for the second quarter (Q2) and first half of 2020.
Q2 and first-half revenue were $5.1 billion and $10.7 billion, respectively, down 10.5 percent and 2.7 percent year-on-year, while Q2 reported a net loss of $3.3 billion, compared with a net profit of $1.88 billion a year earlier.
Gilead said the net loss was mainly related to the acquisition of Forty Seven, which involved $4.5bn in related expenses. The main reasons for the decrease in total revenue from
include: reduced visits and screenings by healthcare providers as a result of the outbreak, which led to a decrease in sales of "flow products" anti-chronic hepatitis C virus (HCV) drugs, and the introduction of generic drugs in the first half of 2019, resulting in a decline in sales of the pulmonary hypertensive treatment drug Letairis ® and chronic angina ®, the.
at the same time, Gilead's core BUSINESS for HIV showed potential growth in demand, and while sales of Truvada products declined during Q2, patients were able to continue to receive Biktarvy and Descovy for pre-exposure prophylaxis (PrEP).
q2 HIV product sales fell just 1 percent in 2020 compared with $4 billion and $7.7 billion in revenue for the same period in 2019, while total sales in the first half increased 6 percent to $8.1 billion.
's revenue growth in the first half of the year was largely based on the potential advantages shown by HIV franchises, particularly Biktarvy's share of the U.S. market and Gilead's overall share of THE HIV sector.
notable, yescarta
increased sales in Q2 in 2020 and $296 million in the first half of 2020, up 30 per cent and 37 per cent year-on-year, mainly due to the continued growth of the treatment's share in the European market. In addition,
, Gilead's research and development pipeline construction has also made important progress.
in oncology, including Kite's portfolio of cell therapies and the acquisition of Forty Seven's magrolimab, which combines azacitidine spent treating hyperplasia syndrome and acute myeloid leukemia.
in hiv, Gilead is developing a new research HIV-1 shell inhibitor lenacapavir as a persistent long-acting subcutaneous agent for HIV infection with other antiviral drugs; The data showed no increase in sexual health risk behavior in patients using Descovy or Truvada for PrEP, and dose-dependent immune response data from the study of the toll-like receptor 7 (TL7R) agonising agent vesatolimod updated Gilead's therapeutic research.
in the case of inflammatory diseases, Gilead, in collaboration with Galapagos, conducted the latest analysis of two clinical trials of the JAK inhibitor filgotinib for adult psoriasis arthritis;
In July this year, the European Medicines Agency (EMA) Human Products Board (CHMP) recommended filgotinib for the treatment of adults with moderate to severe rheumatoid arthritis who do not respond adequately or intolerance to one or more anti-rheumatoid drugs.
in addition to advancing Redsewe's key work, Gilead continues to strengthen its influence in immuno-oncology, including six immuno-oncology agreements reached this year.
the FDA recently accelerated the approval of Tecartus (brexu cabtagene autoleucel) as the first and only CAR-T cell therapy approved for the treatment of recurrent or refractive jacket cell lymphoma in adults.
.